Merck protease inhibitor: more news from Retroviruses Conference.
James
J S
JS
D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D019259:Lamivudine; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D011725:Pyridines; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine; D016049:Didanosine